<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638144</url>
  </required_header>
  <id_info>
    <org_study_id>4109</org_study_id>
    <nct_id>NCT00638144</nct_id>
  </id_info>
  <brief_title>Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C</brief_title>
  <official_title>Prevention of Graft Reinfection After Liver Transplantation for HCV Related End-stage Liver Disease . Study of Humoral Anti-HCV Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      End stage HCV-related cirrhosis has become a major indication for liver transplantation (LT).
      Unfortunately, recurrence of HCV infection on the liver graft occurs in almost all patients
      following transplantation and causes a persistent infection that leads to chronic hepatitis
      and cirrhosis in a significant proportion of patients. To date there is no effective way to
      prevent HCV reinfection of the liver graft in the early phase after transplantation. . Early
      passive immunotherapy with neutralizing antibodies against HCV should be considered for
      preventing reinfection of liver transplanted patients associated with HCV. This approach is
      well established in the case of patients undergoing liver transplantation for chronic
      hepatitis B virus infection. Our purpose is to produce neutralizing monoclonal antibodies to
      prevent reinfection of the liver graft.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>patients with resolved infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>chronically infected patients</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with resolved infection chronically infected patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Health insurance

          -  Resolved HCV infection ( HCV RNA negative since more then 6 months ) -HCV chronically
             infected ( RNA positive )

          -  Anti- HCV antibodies positive

          -  Volunteers and informed patients

        Exclusion Criteria:

          -  Immunosuppression

          -  HBV or HIV infection

          -  Pregnancy

          -  Breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel DOFFOEL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert FARADJI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe WOLF, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BAUMERT Thomas, MD</last_name>
    <phone>00 333 90 24 36 99</phone>
    <email>thomas.baumert@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Françoise STOLL-KELLER, MD</last_name>
    <phone>00 333 90 24 37 16</phone>
    <email>francoise.stoll@viro-ulp.u-strasbg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Hépato-Gastro-Entérologie - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel DOFFOEL, MD</last_name>
      <phone>00 333 88 11 62 49</phone>
      <email>michel.doffoel@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Michel DOFFOEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed ANANNA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François HABERSETZER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie et Oncologie - Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert FARADJI, MD</last_name>
      <phone>00333.88.12.76 90</phone>
      <email>albert.faradji@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Albert FARADJI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Générale et Transplantation Multiorganes - Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe WOLF, MD</last_name>
      <phone>00333 88 12 72 78</phone>
      <email>philippe.wolf@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe WOLF, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard ELLERO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Lorraine WOEHL-JAEGLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2008</study_first_submitted>
  <study_first_submitted_qc>March 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>September 29, 2015</last_update_submitted>
  <last_update_submitted_qc>September 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>liver transplantation</keyword>
  <keyword>antibodies mediated neutralization</keyword>
  <keyword>monoclonal antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

